Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	2,137	2,731	2,745	8,799	3,214	717
Market Cap Growth	-19.40%	-0.54%	-68.80%	173.78%	348.19%	20.99%
Enterprise Value	1,456	1,934	1,683	8,125	2,656	456
PE Ratio	-	-5.67	-5.79	-32.85	-23.94	-7.20
PS Ratio	40.62	75.27	52.67	266.22	55.42	16.64
PB Ratio	2.06	2.60	2.22	8.46	6.10	2.66
P/FCF Ratio	-6.32	-6.69	-7.92	-37.01	-60.08	-6.52
P/OCF Ratio	-6.52	-6.93	-8.24	-39.10	-64.39	-6.95
EV/Sales Ratio	27.69	53.31	32.30	245.81	45.80	10.57
EV/EBITDA Ratio	-4.12	-4.09	-3.61	-31.13	-20.76	-4.85
EV/EBIT Ratio	-4.04	-4.02	-3.55	-30.33	-19.79	-4.58
EV/FCF Ratio	-4.70	-4.74	-4.86	-34.17	-49.65	-4.14
Debt / Equity Ratio	0.11	0.11	0.11	0.07	0.07	0.07
Debt / EBITDA Ratio	-0.23	-0.24	-0.28	-0.28	-0.31	-0.20
Debt / FCF Ratio	-0.27	-0.28	-0.38	-0.31	-0.73	-0.17
Quick Ratio	8.45	8.23	9.45	5.97	9.33	7.98
Current Ratio	9.03	8.66	9.62	6.11	9.60	8.12
Asset Turnover	0.04	0.03	0.04	0.03	0.12	0.13
Return on Equity (ROE)	-45.90%	-43.90%	-48.70%	-33.60%	-36.90%	-36.60%
Return on Assets (ROA)	-37.90%	-36.40%	-38.60%	-26.70%	-27.70%	-28.90%
Return on Capital (ROIC)	-45.10%	-44.21%	-33.53%	-24.04%	-24.12%	-36.90%
Earnings Yield	-22.72%	-17.62%	-17.27%	-3.04%	-4.18%	-13.88%
FCF Yield	-19.56%	-14.94%	-12.63%	-2.70%	-1.66%	-15.34%
Buyback Yield / Dilution	-8.81%	-15.33%	-8.57%	-26.63%	-18.50%	-9.70%
Total Shareholder Return	-8.81%	-15.33%	-8.57%	-26.63%	-18.50%	-9.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).